CNO · CNO Financial Group, Inc.
Market Cap
$5.13B
Shares
92.52M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$55.37
Open$55.33
Day$55.02–55.67
52W close$38.49–55.68
Avg vol 30d659K
Short int1.7M · 1.8% float · 2.8d
Short vol49%
Last earningsJul 31, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 1, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very Low
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+21%
above
Price vs 50-day avg
+4%
above
RSI (14)
61
neutral
MACD trend
Negative
52-week position
98%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+34%
trailing
YTD return
+30%
this year
Relative strength
+21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $53 › 200d $46 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +60 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.83% of float · ▲ +8.7% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
383 holders — near 3-yr high, broad support
Squeeze score
46
elevated · 0–100
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
−41%
Y/Y
Valuation
P/E 19.1
in line
Buyback
$300.4M
remaining
Balance sheet
$260.2M
net debt
Quant / Vol
risk profile
Volatility
21%
annualized · 1-yr
Max drawdown
−11%
past year
ATR
1.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
2026 full year
Operating EPS
Non-GAAP
Raised
$4.60 – $4.80
Apr 30, 2026
$4.25 – $4.45
changed to
Jul 30, 2026
$4.60 – $4.80
Free cash flow
Initiated
$200M – $250M
Effective tax rate
Maintained
21.5%
Jun 30, 2026
21.5%
changed to
Jul 30, 2026
21.5%
RBC Ratio
Initiated
360% – 390%
Minimum holding company liquidity
Initiated
at least $150M
2026
Holding company liquidity
at least $150M
Prior guidance
period ended
· from the 8-K filed Nov 3, 2025
Operating EPS
· 2025
$3.75 – $3.85
Excess cash flow to holding company
· 2025
$365M – $385M
Minimum holding company liquidity
· 2025
$150M
Consolidated RBC ratio target
· 2025
375%
Expense ratio
· 2025
19%
Target leverage
· 2025
25% – 28%
Guided vs delivered
· last 1 settled
Operating earnings per share
full-year 2023
guided $2.65 – $2.85
$2.40
Miss −12.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+21%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
61
Neutral
MACD trend
Negative
Bearish
52-week position
98%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $53 › 200d $46 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +60 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.83% of float · ▲ +8.7% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
383 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $38
Now $55 · 98%
Range high $56
vs 200-day avg +21%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Annuity margin | $60.6M | Three months ended June 30, 2026 filing | — |
|
|
|||
| Fee revenue | $18.5M | Three months ended June 30, 2026 filing | — |
|
|
|||
| Health margin | $147.2M | Three months ended June 30, 2026 filing | — |
|
|
|||
| Income from insurance products | $126.1M | Three months ended June 30, 2026 filing | — |
| Insurance product margin | $279M | Three months ended June 30, 2026 filing | — |
| Life margin | $71.2M | Three months ended June 30, 2026 filing | — |
|
|
|||
| Net Consumer Division fee income (loss) | -$1.2M | Three months ended June 30, 2026 filing | — |
| Operating earnings before taxes non-GAAP | $151M | Three months ended June 30, 2026 filing | — |
|
|
|||
| Total allocated and unallocated expenses non-GAAP | $176.2M | Three months ended June 30, 2026 filing | — |
| Total investment income not allocated to product lines | $49.4M | Three months ended June 30, 2026 filing | — |
| Average yield on allocated investments | 4.91% | 2Q26 | — |
|
|
|||
| Book value per diluted share, excluding accumulated other comprehensive income (loss) non-GAAP | $39.92 | 2Q26 | — |
| Client Assets in Brokerage and Advisory | 5.69B | 2Q26 | — |
| consolidated statutory risk-based capital ratio non-GAAP | 377% | 2Q26 | — |
|
|
|||
| Debt to Capital non-GAAP | 26.1% | 2Q26 | — |
| Earned yield | 4.88% | 2Q26 | — |
|
|
|||
| Expense Ratio non-GAAP | 18.4% | 2Q26 | — |
|
|
|||
| Free Cash Flow non-GAAP | 30.7M | 2Q26 | — |
|
|
|||
| Insurance Product Margin Excluding Significant Items non-GAAP | 279M | 2Q26 | — |
| Net New Client Assets in Brokerage and Advisory | 195.7M | 2Q26 | — |
|
|
|||
| Net operating income non-GAAP | $119.5M | 2Q26 | — |
|
|
|||
| New money rate | 6.16% | 2Q26 | — |
|
|
|||
| Registered Agent Counts | 792 | 2Q26 | — |
|
|
|||
| Rolling Twelve Months Expense Ratio non-GAAP | 18.5% | 2Q26 | — |
| Total Net Investment Income non-GAAP | 327.5M | 2Q26 | — |
|
|
|||
| TTM operating ROE non-GAAP | 14.1% | 2Q26 | — |
| Value of NOLs | 189M | as of June 30, 2026 | — |
| Annuity Collected Premiums | $433.8M | 1Q26 | — |
| Annuity insurance product margin excluding significant items non-GAAP | $58.5M | 1Q26 | — |
| associates | 3,300 | 1Q26 | — |
| average cost per share | $41.79 | 1Q26 | — |
| Book value per common share | $26.64 | as of March 31, 2026 | — |
| Book value per diluted share excluding AOCI non-GAAP | $38.98 | 1Q26 | — |
|
|
|||
| common shares outstanding | 93.8M | as of March 31, 2026 | — |
| common shares repurchased | 1.4M | 1Q26 | — |
| common stock repurchased | $60M | 1Q26 | — |
| Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating non-GAAP | $3.46B | 1Q26 | — |
| Consolidated Risk Based Capital (RBC) Ratio non-GAAP | 375% | 1Q26 | — |
| Consumer Fee Revenue non-GAAP | $42.8M | 1Q26 | — |
| Consumer New Annualized Premiums | $99.8M | 1Q26 | — |
| Debt to capital excluding AOCI non-GAAP | 26.4% | 1Q26 | — |
| debt-to-capital ratio | 34.8% | as of March 31, 2026 | — |
| debt-to-total capital ratio, excluding accumulated other comprehensive income (loss) non-GAAP | 26.4% | as of March 31, 2026 | — |
| dividends paid on common stock | $17.1M | 1Q26 | — |
| exclusive agents | 5,000 | 1Q26 | — |
| Health insurance product margin excluding significant items non-GAAP | $132.6M | 1Q26 | — |
| Holding Company Liquidity | $280M | 1Q26 | — |
| independent partner agents | 7,500 | 1Q26 | — |
| Investment Income Allocated to Product Lines non-GAAP | $273.5M | 1Q26 | — |
| Investment Income Not Allocated to Product Lines non-GAAP | $41.7M | 1Q26 | — |
| Life insurance product margin excluding significant items non-GAAP | $65.8M | 1Q26 | — |
| Net operating income, excluding significant items - trailing four quarters non-GAAP | 427.2M | 1Q26 | — |
|
|
|||
| New Annualized Premiums | $117.4M | 1Q26 | — |
| Operating return on equity, excluding accumulated other comprehensive income (loss) and net oper non-GAAP | 13.1% | 1Q26 | +4.8% |
|
|
|||
| Operating return on equity, excluding significant items, accumulated other comprehensive income non-GAAP | 12.2% | 1Q26 | +2.5% |
|
|
|||
| policies | 3.3M | 1Q26 | — |
| Policyholder account balances, end of period excluding contracts 100% ceded (Total annuities) | $13.42B | 1Q 2026 | — |
| remaining repurchase authority | $360.4M | as of March 31, 2026 | — |
| Risk-based capital ratio | 375% | 1Q 2026 | — |
| statutory operating gain non-GAAP | $23M | 1Q26 | — |
| Total annuity margin | $58.5M | 1Q 2026 | — |
| Total collected premiums | $1.11B | 1Q 2026 | — |
|
|
|||
| Total Consumer Division health and life NAP | $99.8M | 1Q 2026 | — |
| Total health margin | $132.6M | 1Q 2026 | — |
|
|
|||
| Total health margin/insurance policy income | 31% | 1Q 2026 | — |
| Total insurance policy income | $673.4M | 1Q 2026 | — |
| Total insurance product margin excluding significant items non-GAAP | $256.9M | 1Q26 | — |
| Total NAP | $117.4M | 1Q 2026 | — |
|
|
|||
| Total Worksite Division health and life NAP | $17.6M | 1Q 2026 | — |
| Unrestricted cash and investments held by holding company | $280.1M | as of March 31, 2026 | — |
| Worksite New Annualized Premiums | $17.6M | 1Q26 | — |
| 4Q25 General Account New Money Purchases | $1.63B | 4Q25 | — |
| Available Cash and Investments, End of Period | $351.4M | FY2025 | — |
| Average book value of invested assets | 3.5% | 4Q25 | — |
| Average Book Value of Investments & Cash | 31.46B | 4Q FY2025 | — |
| Book value per common share, excluding accumulated other comprehensive loss non-GAAP | $39.72 | Q4 2025 | — |
| Book value per diluted share, excluding accumulated other comprehensive loss non-GAAP | $38.81 | Q4 2025 | — |
GAAP → non-GAAP reconciliationGAAP Book value per diluted share $27.28
+$11.53 Accumulated other comprehensive loss per diluted share
= Book value per diluted share, excluding accumulated other comprehensive loss $38.81
|
|||
| Capital returned to shareholders | 386M | FY2025 | — |
| Client Assets in Brokerage and Advisory at end of period | $5.04B | 4Q25 | — |
| Debt to total capital ratio, excluding AOCI non-GAAP | 26.2% | 2025 | — |
| Expense Ratio - YTD non-GAAP | 18.9% | FY2025 | — |
| Expense ratio excluding significant items non-GAAP | 18.9% | FY2025 | — |
| Invested Assets | 31B | 4Q25 | — |
| Margin from interest sensitive life | $24.8M | 4Q 2025 | — |
| Margin from long-term care | $36.7M | 4Q 2025 | — |
| Margin from Medicare supplement | $28.6M | 4Q 2025 | — |
| Margin from supplemental health | $74.1M | 4Q 2025 | — |
| Margin from traditional life | $45.2M | 4Q 2025 | — |
| Net operating income excluding significant items non-GAAP | 401.7M | FY2025 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net operating income $439.2M
-$37.5M Significant items
= Net operating income, excluding significant items $401.7M
|
|||
| Net operating income per diluted share non-GAAP | $4.4 | Year ended December 31, 2025 | — |
|
|
|||
| Net operating income per diluted share excluding significant items non-GAAP | $4.02 | FY2025 | — |
| Operating EPS non-GAAP | $4.4 | FY2025 | — |
| Operating EPS excluding significant items non-GAAP | $4.02 | FY2025 | — |
| Operating income non-GAAP | $439.2M | 4Q25 | — |
|
|
|||
| Operating income, excluding significant items non-GAAP | $401.7M | 4Q25 | — |
|
|
|||
| Operating ROE non-GAAP | 12.4% | FY2025 | — |
| Operating ROE excluding significant items non-GAAP | 11.4% | FY2025 | — |
| Pre-tax operating earnings non-GAAP | $553.2M | Year ended December 31, 2025 | — |
| Pre-tax operating earnings (a non-GAAP financial measure) non-GAAP | $553.2M | 4Q25 | — |
| Producing Agent Counts (PAC) non-GAAP | 5,016 | 4Q FY2025 | — |
| Rolling Twelve Months Ratio (Expense Ratio) non-GAAP | 18.9% | FY2025 | — |
| Share repurchases | 320M | FY2025 | — |
| Total health NAP | $83M | 4Q 2025 | — |
| Total insurance product margin | $1.07B | Year ended December 31, 2025 | — |
| Total life margin | $70M | 4Q 2025 | — |
| Total life NAP | $45.5M | 4Q 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Insurance - Life — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNO
this stock
CNO Financial Group, Inc.
|
$5.13B | +30.4% | +0.9% | 19.1 | 1.8% |
|
CILJF
China Life Insurance Co Ltd
|
$105.43B | +8.7% | — | — | 0.0% |
|
MFC
Manulife Financial Corp
|
$71.71B | +17.9% | — | — | 1.3% |
|
MET
Metlife Inc
|
$61.16B | +22.3% | +8.6% | 18.4 | 1.8% |
|
AFL
Aflac Inc
|
$58.42B | +5.7% | -9.3% | 12.6 | 2.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNO | +3.5% | +0.5% | +34.5% | +0.5% | +30.4% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +3.0% | -2.5% | +21.1% | -2.5% | +17.6% |
Capital returns
Latest dividend
$0.18
/ share · ex Jun 10, 2026
Declared · upcoming
$0.18
/ share · ex Sep 10, 2026
Paid (TTM)
$0.69
/ share · 4 payouts
Dividend yield (TTM, derived)
1.25%
Buyback program
· as of Jun 30, 2026
Authorized
$500.00M
Spent (derived)
$199.60M
Remaining
$300.40M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1224608
CUSIP
12621E103
13F (30d)
301 filings
298 filers
Visit website
Investor relations